Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Takeda’s Cx601 Stem Cell Therapy Hits Primary Endpoint in Global PIII
August 3, 2016
- Shionogi to Transfer 21 Off-Patent Products to Kyowa Pharm
August 3, 2016
- Opdivo Hauls in 25.2 Billion Yen in April-June
August 3, 2016
- Nichi-Iko Launches Tender Offer for Sagent
August 3, 2016
- Japan Market Grows in April-June on Hep C Meds, Opdivo: IMS
August 2, 2016
- Gil Feldman Picked as President of Teva API Japan
August 2, 2016
- Halaven Extends Duration of Response in Soft Tissue Sarcoma: Global PIII
August 2, 2016
- Sunovion Submits US NDA for COPD Drug
August 2, 2016
- Positive Changes Seen in Oncology R&D under New Head: Daiichi Sankyo CEO
August 2, 2016
- Kyowa Kirin to Stress Effectiveness of Psoriasis Drug Lumicef in Promotion: President
August 2, 2016
- Takeda to Revamp R&D Organization, Eyes Consolidated Research Sites in Japan, US
August 1, 2016
- Janssen Files HIV Combo Pill in Japan
August 1, 2016
- Otsuka Ups January-June Profit Forecasts
August 1, 2016
- Taiho Seeks Two Add’l Indications for Zosyn
August 1, 2016
- Chugai Hemophilia A Treatment Yields Positive Data in Japan PI/II
July 29, 2016
- Astellas, Cytokinetics Expand Collaboration into ALS
July 29, 2016
- Damage Suit Filed over HPV Vaccines; MSD Says Claims Scientifically Unfounded
July 28, 2016
- Teijin Files Somatuline for Neuroendocrine Tumor in Japan
July 28, 2016
- Ono Seeks Japan OK for Opdivo’s Head and Neck Cancer Indication
July 28, 2016
- Sumitomo Dainippon Trio to Research Method for Pre-RPE Cell Transplant Immune Reaction Testing
July 27, 2016
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…